Print-Friendly PDF Print this page

John Egan, a partner in and co-chair of the firm’s Technology Companies & Life Sciences Group, focuses on corporate securities, venture capital, growth equity and technology enterprises. Mr. Egan is a key contributor to the Goodwin Procter Founders Workbench, an online resource for start-ups, emerging companies and the entrepreneurial community. He rejoined Goodwin Procter in 2005.

Mr. Egan’s practice involves early and late-stage venture financings, growth equity and leveraged recapitalizations, IPOs, mergers and acquisitions, joint ventures, strategic licensing and the general representation of public and private emerging growth companies in industries ranging from enterprise software, networking, security and business services to communications, media and life sciences. He also represents numerous venture capitalists, private equity investors and investment banks and has extensive experience in intellectual property and licensing issues.

Prior to rejoining Goodwin Procter, Mr. Egan was a partner at McDermott Will & Emery in Boston, where he was a member of that firm's Corporate Department and global head of its Private Equity/Emerging Companies Group.

Exit Strategies
March 10, 2011
New York, NY